Full Press Release Details
REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS and PLANS TO FILE FORM 12b-25 to extend filing date of its form
Calif., March 31, 2023 (GLOBE NEWSWIRE) - Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company, today announced
plans to file a Form 12b-25 with the U.S. Securities and Exchange Commission regarding its Annual Report on Form 10-K and reports preliminary
financial results for the full year ended December 31, 2022. The Company is completing its final review of the information required to
be presented for the relevant period. The Form 12b-25 provides the Company with an additional 15 calendar days to complete its assessment
and allows its independent registered public accounting firm extra time to complete its audit of the Company's financial statements
before filing its Form 10-K reports.
Company currently anticipates filing the 2022 Form 10-K as soon as practicable and expects that, in compliance with Rule 12b-25, it will
be filed no later than April 17, 2023.
Company continues to work diligently to submit the filing. Turning to our recent performance, we have committed to a strategic shift
from a service lab model to a product-driven revenue model with low-cost infrastructure and scalable high-margin distributable content"
said Joshua Riggs, CEO. "With a reduced cash burn, we believe this puts us in a better position to support the future of our core
products and rapidly deliver on our major milestones ahead. We are confident that a kitted product approach puts our unique technology
in the hands of researchers at every level, from pharma to academia, encouraging research on the role of the tumor microenvironment in
oncology and transplant graft health and viability."
| Appointed Joshua Riggs to President, CEO, and to its Board of Directors | ||
| Appointed seasoned healthcare executive Lou Silverman to its Board of Directors as Lead Independent Director | ||
| Announced the divestiture of DetermaRx, resulting in expected savings of approximately $30 million in operating cost and development obligations over the next two years | ||
| Implemented cost reduction plans to drive expected quarterly average 2H 2023 cash burn below $6 million, down from $10.5 million in 2H 2022 | ||
| Focused development of VitaGraft and DetermaIO in 2023 with DetermaCNI in development pipeline for 2024 | ||
| Entered into an amendment to the Chronix Merger Agreement in February 2022 to reduce contingent liabilities and open a kitting opportunity for VitaGraft | ||
| Completed VitaGraft RUO feasibility, anticipated to enter pre-manufacturing optimization in 2Q 2023 | ||
| Initiated DetermaIO multicenter SWOG study for Triple Negative Breast Cancer and had Metastatic Colorectal Cancer data accepted for publication in Clinical Cancer Research | ||
| Submitted DetermaIO reimbursement dossier to MolDx in December 2022 |
Preliminary Financial Results
revenues for the three and twelve months ended December 31, 2022, were approximately $1.1 million and $5.6 million, respectively, a decrease
of 69% compared to fourth quarter 2021 and 27% compared to the full year 2021. Excluding DetermaRx revenue, the continuing operations
revenue was $1.0 million for the year ended December 31, 2022.
DetermaRx revenues for the three months ended December
31, 2022 were $0.8 million, a 3% increase from the same period in 2021. Consolidated DetermaRx revenues for the year ended December
31, 2022, were approximately $3.6 million, a 47% percent increase from the previous year.
cost of revenues for the three months ended December
31, 2022 were approximately $2.4 million, including $1.6 million from the cost of diagnostic tests and testing services we performed
for our pharma customers, and approximately $0.8 million in noncash amortization expense.
cost of revenues for the year ended December 31,
2022 were approximately $8.9 million, including $5.2 million from the cost of diagnostic tests and testing services we performed for
our pharma customers, and $3.7 million in noncash amortization expense. Cost of revenues for continuing operations were approximately
operating expenses for the year ended December 31,
2022 were approximately $69.0 million, including $22.4 million from general and administrative, $19.4 million from
research and development, $13.6 million from sales and marketing, $31.0 million gain from change in fair value of contingent
consideration, $44.6 million from impairment loss. Operating expenses from continuing operations for the year ended December 31, 2022
were approximately $18.0 million.
Company will host a conference call on April 3rd at 8:30 am EDT / 5:30 am PDT to discuss the results along with recent
corporate developments. The dial-in number in the U.S./Canada is 1-877-407-9716; for international participants, the number is 1-201-493-6779.
To access the live webcast, go to the investor relations section on the Company's website, or by clicking here: https://viavid.webcasts.com/starthere.jsp?ei=1596927&tp_key=b228274c7e.
A webcast replay will be available on the Oncocyte website for 90 days following the completion of the call.
is a precision diagnostics company. The Company's tests are designed to help provide clarity and confidence to physicians and their
patients. DetermaIO is a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies.
VitaGraft is a blood-based solid organ transplantation monitoring test, and pipeline test DetermaCNI is blood-based monitoring
tool for monitoring therapeutic efficacy.
DetermaCNI , and VitaGraft are trademarks of Oncocyte Corporation
Forward Looking Statements
statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes,"
"plans," "anticipates," "expects," "estimates," "may," and similar expressions)
are forward-looking statements. These statements include those pertaining to, among other things, the expectation that the Company's
cash runway can support future product development milestones, the expected savings of approximately $30 million in operating
cost & development obligations over the next two years as a result of the divestiture of DetermaRx, the expectation
that cost reduction plans will drive quarterly average 2H 2023 cash burn below $6M, the anticipation that DetermaCNI will be in the
development pipeline for 2024, the anticipation of kitting opportunities for VitaGraft, the anticipation that VitaGraft RUO will enter
pre-manufacturing optimization in Q2 2023, the belief that the Company is poised to rapidly deliver on major milestones, the belief
that a kitted product approach will put the Company's unique technology in the hands of researchers at every level and encourage
research on the role of the tumor microenvironment in oncology and transplant graft health and viability, and other statements about
the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties,
including, without limitation, the potential impact of the recent COVID-19 pandemic on Oncocyte or its subsidiaries' financial
and operational results, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the
results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system
to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability
to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, obligations to third parties with
respect to licensed or acquired technology and products, the need to obtain third party reimbursement for patients' use of any
diagnostic tests Oncocyte or its subsidiaries commercialize in applicable jurisdictions, and risks inherent in strategic transactions
such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions,
accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies,
or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results
anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties
that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors" and other cautionary statements
found in Oncocyte's Securities and Exchange Commission (SEC) filings, which are available from the SEC's website. You are
cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte
undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they
were made, except as required by law.
CONSOLIDATED BALANCE SHEETS
| December 31, | ||||||||
| 2022 | 2021 | |||||||
| ASSETS | ||||||||
| CURRENT ASSETS | ||||||||
| Cash and cash equivalents | $ | 19,993 | $ | 32,948 | ||||
| Accounts receivable, net | 2,012 | 1,437 | ||||||
| Marketable equity securities | 433 | 904 | ||||||
| Prepaid expenses and other current assets | 977 | 901 | ||||||
| Current assets of discontinuing operations | 2,121 | 2,953 | ||||||
| Total current assets | 25,536 | 39,143 | ||||||
| NONCURRENT ASSETS | ||||||||
| Right-of-use and financing lease assets, net | 2,088 | 2,779 | ||||||
| Machinery and equipment, net, and construction in progress | 8,763 | 5,590 | ||||||
| Goodwill | - | 18,684 | ||||||
| Intangible assets, net | 61,633 | 61,721 | ||||||
| Restricted cash | 1,700 | 1,700 | ||||||
| Other noncurrent assets | 371 | 264 | ||||||
| Other noncurrent assets of discontinuing operations | - | 29,682 | ||||||
| TOTAL ASSETS | $ | 100,091 | $ | 159,563 | ||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||
| CURRENT LIABILITIES | ||||||||
| Accounts payable | $ | 1,253 | $ | 1,810 | ||||
| Accrued compensation | 1,771 | 3,092 | ||||||
| Accrued expenses and other current liabilities | 3,839 | 2,085 | ||||||
| Accrued severance from acquisition | 2,314 | 2,352 | ||||||
| Accrued liabilities from acquisition | 109 | 1,388 | ||||||
| Loans payable, net of deferred financing costs | - | 1,313 | ||||||
| Right-of-use and financing lease liabilities, current | 815 | 819 | ||||||
| Current liabilities of discontinuing operations | 2,005 | 1,261 | ||||||
| Total current liabilities | 12,106 | 14,120 | ||||||
| NONCURRENT LIABILITIES | ||||||||
| Right-of-use and financing lease liabilities, noncurrent | 2,729 | 3,545 | ||||||
| Contingent consideration liabilities | 45,662 | 76,681 | ||||||
| TOTAL LIABILITIES | 60,497 | 94,346 | ||||||
| COMMITMENTS AND CONTINGENCIES | ||||||||
| Series A Redeemable Convertible Preferred Stock, no par value; stated value $1,000 per share; 6 shares issued and outstanding at December 31, 2022; aggregate liquidation preference of $6,091 as of December 31, 2022 | 5,302 | - | ||||||
| SHAREHOLDERS' EQUITY | ||||||||
| Preferred stock, no par value, 5,000 shares authorized; no shares issued and outstanding | - | - | ||||||
| Common stock, no par value, 230,000 shares authorized; 118,644 and 92,232 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively | 294,929 | 252,954 | ||||||
| Accumulated other comprehensive income | 39 | 37 | ||||||
| Accumulated deficit | (260,676 | ) | (187,774 | ) | ||||
| Total shareholders' equity | 34,292 | 65,217 | ||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | $ | 100,091 | $ | 159,563 |
CONSOLIDATED STATEMENTS OF OPERATIONS
thousands, except per share data)
| Year Ended December 31, | ||||||||
| 2022 | 2021 | |||||||
| Net revenue | $ | 958 | $ | 2,198 | ||||
| Cost of revenues | 880 | 697 | ||||||
| Cost of revenues - amortization of acquired intangibles | 96 | 81 | ||||||
| Gross margin | (18 | ) | 1,420 | |||||
| Operating expenses: | ||||||||
| Research and development | 7,301 | 5,035 | ||||||
| Sales and marketing | 1,132 | 552 | ||||||
| General and administrative | 21,881 | 22,205 | ||||||
| Change in fair value of contingent consideration | (31,019 | ) | 27,266 | |||||
| Loss from goodwill impairment | 18,684 | - | ||||||
| Loss from held for sale assets | - | |||||||
| Total operating expenses | $ | 17,979 | $ | 55,058 | ||||
| Loss from operations | $ | (17,997 | ) | $ | (53,638 | ) | ||
| OTHER INCOME (EXPENSES), NET | ||||||||
| Interest expense, net | (77 | ) | (209 | ) | ||||
| Unrealized gain (loss) on marketable equity securities | (471 | ) | 229 | |||||
| Pro rata loss from equity method investment in Razor | - | (270 | ) | |||||
| Gain on extinguishment of debt (PPP loan) | - | 1,141 | ||||||
| Other expenses, net | (67 | ) | (37 | ) | ||||
| Total other income (expenses), net | (615 | ) | 854 | |||||
| LOSS BEFORE INCOME TAXES | (18,612 | ) | (52,784 | ) | ||||
| Income tax benefit | - | 9,261 | ||||||
| Loss from continuing operations | (18,612 | ) | (43,523 | ) | ||||
| Loss from discontinued operations | (54,290 | ) | (20,574 | ) | ||||
| NET LOSS | (72,902 | ) | (64,097 | ) | ||||
| Accretion of Series A redeemable convertible preferred stock | (520 | ) | - | |||||
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS: BASIC AND DILUTED | (73,422 | ) | (64,097 | ) | ||||
| Net loss per share from continuing operations, basic and diluted | $ | (0.17 | ) | $ | (0.49 | ) | ||
| Net loss per share from discontinuing operations, basic and diluted | $ | (0.49 | ) | $ | (0.23 | ) | ||
| Net loss per share: basic and diluted | (1 | ) | (1 | ) | ||||
| Weighted average shares outstanding: basic and diluted | 110,800 | 88,920 |
Reconciliation of Non-GAAP Financial Measure
Loss from Operations
| For the Three Months Ended | For the Year Ended | |||||||||||||||
| December 31, | December 31, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| (unaudited) | (unaudited) | (unaudited) | (unaudited) | |||||||||||||
| Consolidated GAAP loss from operations - as reported | $ | (44,664 | ) | $ | (35,680 | ) | $ | (72,287 | ) | $ | (74,212 | ) | ||||
| Stock-based compensation expense | 2,619 | 1,706 | 10,042 | 6,841 | ||||||||||||
| Change in fair value of contingent consideration | (13,862 | ) | 25,006 | (31,019 | ) | 27,266 | ||||||||||
| Severance charge | 1,640 | 255 | 2,829 | 2,707 | ||||||||||||
| Depreciation and amortization expense | 1,278 | 1,251 | 5,220 | 4,205 | ||||||||||||
| Impairment loss | 44,550 | - | 44,550 | - | ||||||||||||
| Consolidated Non-GAAP loss from operations, as adjusted | $ | (8,439 | ) | $ | (7,462 | ) | $ | (40,665 | ) | $ | (33,193 | ) |